Estrogens, Conjugated

Summary

Estrogens, Conjugated (CHEMBL1201649) is an approved unknown (ATC G03CA57); indicated across 39 conditions including postmenopausal osteoporosis and osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: G03CA57
• Indications: 39 conditions
• Clinical trials: 32

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201649
Name	Estrogens, Conjugated
Type	Unknown
Max phase	4
ATC	G03CA57

Also known as: Conjugated estrogens, Estrogen, conjugated (class), Estrogens conjugated, Estrogens, conjugated, conjugated component of duavee, conjugated component of prempro, G03CA57, Oestrogens conjugated, Premarin, ESTROGENS, CONJUGATED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

39 indications (10 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
postmenopausal osteoporosis	4	MONDO:0008159	EFO:0003854
osteoporosis	4	MONDO:0005298	EFO:0003882
primary ovarian failure	4	MONDO:0005387	EFO:0004266
breast neoplasm	4	MONDO:0021100	EFO:0003869
psychologic dyspareunia	4	MONDO:0001196	HP:0030016
postmenopausal atrophic vaginitis	4	MONDO:0001410	MONDO:0001410
hypogonadism	4	MONDO:0002146	MONDO:0002146
myocardial infarction	3	MONDO:0005068	EFO:0000612
stroke disorder	3	MONDO:0005098	EFO:0000712
coronary artery disorder	3	MONDO:0005010	EFO:0001645
myocardial ischemia	3	MONDO:0024644	EFO:1001375
diabetes mellitus	3	MONDO:0005015	EFO:0000400
hypertensive disorder	3	MONDO:0005044	EFO:0000537
colonic neoplasm	3	MONDO:0005401	EFO:0004288
intermediate coronary syndrome	3	MONDO:0006805	EFO:1000985
thrombotic disease	3	MONDO:0000831	MONDO:0000831
endometrium neoplasm	3	MONDO:0021251	MONDO:0011962
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
Turner syndrome	3	MONDO:0019499	MONDO:0019499
interstitial cystitis	3	MONDO:0018301	EFO:0008507
anorexia nervosa	3	MONDO:0005351	MONDO:0005351
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
heart disorder	3	MONDO:0005267	EFO:0003777
bone disorder	3	MONDO:0005381	EFO:0004260
prostate carcinoma	2	MONDO:0005159	EFO:0001663
overactive bladder	2	MONDO:0006624	EFO:1000781
brain injury	2	MONDO:0043510	MONDO:0043510
ischemia reperfusion injury	1	MONDO:0005203	EFO:0002687

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
PHASE1	10
PHASE2	9
PHASE3	7
PHASE4	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01613170	PHASE4	UNKNOWN	Premarin Versus Toviaz for Treatment of Overactive Bladder
NCT01778985	PHASE4	COMPLETED	Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
NCT02860897	PHASE4	WITHDRAWN	Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery
NCT00000419	PHASE3	TERMINATED	Safety of Estrogens in Lupus: Hormone Replacement Therapy
NCT00000466	PHASE3	COMPLETED	Postmenopausal Estrogen/Progestin Interventions (PEPI)
NCT00000555	PHASE3	COMPLETED	Women’s Angiographic Vitamin and Estrogen Trial (WAVE)
NCT00002976	PHASE3	TERMINATED	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
NCT00004650	PHASE3	COMPLETED	Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
NCT00026286	PHASE3	COMPLETED	Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
NCT00808132	PHASE3	COMPLETED	Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
NCT04821141	PHASE2	ACTIVE_NOT_RECRUITING	Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT00000612	PHASE2	COMPLETED	Soy Estrogen Alternative Study (SEA)
NCT00134654	PHASE2	COMPLETED	Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
NCT00149604	PHASE2	COMPLETED	AFTER: Altering Fat Through Estrogen and Raloxifene
NCT00152282	PHASE2	COMPLETED	A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women
NCT00152295	PHASE2	COMPLETED	A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women
NCT00604825	PHASE2	COMPLETED	Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
NCT02694809	PHASE2	COMPLETED	The PROMISE Study: Duavee in Women With DCIS
NCT05073237	PHASE2	WITHDRAWN	Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans
NCT00318318	PHASE1	COMPLETED	Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array
NCT00396799	PHASE1	COMPLETED	Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women
NCT00401219	PHASE1	COMPLETED	Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation
NCT00472927	PHASE1	COMPLETED	Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
NCT00479778	PHASE1	COMPLETED	Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
NCT00543634	PHASE1	COMPLETED	Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
NCT00550433	PHASE1	COMPLETED	Study Evaluating Bazedoxifene/CE in Postmenopausal Women
NCT00706225	PHASE1	COMPLETED	Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women
NCT00745173	PHASE1	COMPLETED	Study Evaluating Premarin and Bazedoxifene Potential Interaction
NCT01634789	PHASE1	TERMINATED	A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
NCT00079248	Not specified	UNKNOWN	Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
NCT00380887	Not specified	COMPLETED	Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
NCT01023178	Not specified	COMPLETED	Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).